The single protein encoded by Abelson murine leukemia virus is a fusion of sequence from the retroviral gag genes with the v-abl sequence. Deletion of most of the gag region from the transforming protein results in a virus capable of transforming fibroblasts but no longer capable of transforming lymphoid cells. Smaller deletions in gag reveal that p15 gag sequences are responsible for this effect, whereas deletion of p12 sequences had no effect on lymphoid transformation. In transformed fibroblasts, p15-deleted and normal proteins had similar activities and subcellular localization. When the p15-deleted genome was introduced into previously transformed lymphoid lines, its protein product exhibited a marked instability. The tyrosine-specific autophosphorylation activity per cell was less than 1/20th that of the nondeleted protein. Although pulse-labeling showed that the p15-deleted protein was synthesized efficiently, immunoblotting demonstrated that its steady-state level was less than 1/10th that of the nondeleted Abelson protein. The specific instability of the p15-deleted protein in lymphoid cells explains the requirement of these sequences for lymphoid but not fibroblast transformation.
Abelson Murine Leukemia virus (A-MuLV) is a replication-defective retrovirus capable of transforming fibroblast cells in vitro
and lymphoid cells both in vivo and in vitro (1, 26) . The virus arose through recombination between Moloney-MuLV (M-MuLV), a replication-competent retrovirus, and c-abl, a gene normally expressed in many cells (7, 19, 31, 37, 38) . The A-MuLV genome expresses a single gene product partially derived from each parent (23, 44) . It contains 30 kilodaltons (kd) of M-MuLV gag-encoded sequence at its N terminus, followed by variable amounts of v-abl-derived sequence. The gag gene of M-MuLV encodes the viral core antigens in the form of a precursor protein, Pr65gag, which contains p15, pi2, p30, and plO, in that order.
Pr65gag is cleaved into these products during maturation of the virion at the cell surface. The A-MuLV protein contains p15, p12, and a small part of p30 fused to the v-abl-encoded sequence.
The A-MuLV protein displays a protein-tyrosine kinase activity (42) which is apparently essential to the ability of the virus to transform cells (43) . Mutations in the N terminus of v-abl abolish the kinase activity, as well as the transformation activity (20a; J. J.-Y. Wang and D. Baltimore, J. Biol. Chem., in press). The Rous sarcoma virus transforming gene product, pp60sc, as well as that of several other oncogenes (12, 13, 16) and growth factor receptor proteins (6, 11, 15, 34) , has a protein-tyrosine kinase activity. Furthermore, these oncogenes and the epidermal growth factor receptor have extensive amino acid homology through a section of their genes which encodes the tyrosine kinase activity (3, 5) .
There are many variants of A-MuLV containing different segments of v-abl. The largest variant, A-MuLV[P160], encodes a 160-kd protein, including 130 kd encoded by v-abl (9, 27) . Only the N-terminal 45 kd of v-abl protein, contain-* Corresponding author.
ing the kinase domain and amino acid homology to pp60src, is required for fibroblast transformation (21, 22) . Although deletion of the C terminus of v-abl reduces the lymphoid transformation efficiency (27, 39) , we show here that variants with the N-terminal 60 kd of v-abl protein retain the ability to transform lymphoid cells. For ease of reference, we call any v-abl-containing protein an Abelson protein. Deletion of all of the gag sequences in A-MuLV, except for the first 34 amino acids, resulted in a virus which still transformed NIH/3T3 fibroblasts efficiently (21) . Surprisingly, however, the deletion totally abolished the ability of the virus to transform lymphoid cells. Here, we report the effect of smaller deletions in gag. Deletion in p12 had no effect, whereas deletion in p15 abolished lymphoid-transforming activity. As we have not been able to detect any biochemical differences in the p15-deleted protein in transformed fibroblast cells, we introduced the p15-deleted virus into previously transformed lymphoid cells to study its properties in this specific cell type. We find a marked instability of the deleted protein specific to this cell type, resulting in drastically lower steady-state levels of the protein.
MATERIALS AND METHODS Cells and viruses. Normal and A-MuLV-transformed NIH/3T3 cells were grown in Dulbecco modified Eagle's medium with 10% calf serum. A-MuLV titers were determined by focus formation on NIH/3T3 cells (28) . Lymphoid cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum and 50 ,uM 2-mercaptoethanol. In vitro bone marrow transformation in agar and liquid have been described (25, 26) . Transfections of NIH/3T3 cells were as described (41) and modified (21) .
Infections of 70Z/3 and 2M3 cells were performed by resuspending 104 cells in 1.0 ml of a 1:1 dilution of a virus stock (with 8 ,ug of polybrene per ml) from either N2 or NAp15-1 cells. The titers of these stocks were roughly 5 x 105 focus-forming units per ml. After 1.5 h of incubation with virus at 37°C the cells were single-cell cloned into microtiter wells. Single-cell clones were picked after 7 days from 96-well plates with less than 15 positive wells.
Cellular DNA and RNA. The preparation of total cellular DNA, restriction enzyme digestions, gel electrophoresis, and transfer to nitrocellulose (32) were all previously described (9) . 32P-labeled probes were prepared by nick translation (24) .
Total cellular RNA was prepared by the guanidinium thiocyanate method (4), treated with glyoxal, and fractionated by electrophoresis through an agarose gel (18) . The gel was transferred to nitrocellulose and hybridized with a nick-translated v-abl-specific probe.
Labeling, immunoprecipitation, and autophosphorylation. ) . The autophosphorylation reaction was allowed to proceed for 10 min on ice. The pellet was then washed once with 1.0 ml of 50 mM Tris (pH 8) and resuspended in SDS-sample buffer (67 mM Tris [pH 6.8], 2% SDS, 10% glycerol, 5 mM EDTA, 20 mM dithiothreitol, bromophenol blue). The samples were boiled and fractionated by electrophoresis through an SDS-polyacrylamide gel in the standard fashion.
Immunoblotting. A-MuLV proteins were analyzed by immunoblotting essentially as described (33) . Samples were normalized for cell number, extracted in 10 mM Tris (pH 7.5)-0.1 M NaCl-1% Triton X-100-0.5% deoxycholate-0.1% SDS for 10 min on ice, and clarified for 15 min at 13,000 x g. One-half volume of 3 x SDS-sample buffer was added to the supernatants, boiled for 5 min, and fractionated by electrophoresis through a 7% SDS-polyacrylamide gel. The proteins were then transferred to nitrocelluose by using an electroblot apparatus (Bio-Rad Laboratories) at 275 mA for 2 h in 192 mM glycine-25 mM Tris-hydrochloride-20% (vol/vol) methanol. After transfer the filter was soaked for 1 h at room temperature in phosphate-buffered saline (PBS; pH 7.5) with 3% bovine serum albumin and 0.05% Tween 20 (blocking buffer), followed by 1 h at room temperature in blocking buffer containing a 1:1,000 dilution of R-anti-abl. The filter was then washed three times, 10 min each time, in PBS. As a second antibody, goat anti-rabbit immunoglobulin G conjugated to peroxidase (Cappel Laboratories) was used. Table 1 for data on the efficiency of these viruses in lymphoid transformation. NarI site 377 bases 5' of the XhoI site used in pABX2. The position that was the ClaI site of M-MuLV has also been changed to an EcoRI site. These two EcoRI sites were ligated together, deleting the 3' 377 bases of v-abl present in pABX2.
(v) pNApl5. pNApl5 has the exact same deletion as pXApl5 but in pABN2.
(vi) pNdl. pNdl contains a deletion in pABN2 of amino acids 114 to 138 of gag, inserting two amino acids (Asn-Ser) at the junction. The plasmid was generated by treating pXApl2 with EcoRI and then Bal 31 exonuclease. The reaction was terminated, the ends were blunted with the Klenow fragment of E. coli polymerase I, and EcoRI linkers were ligated on. An EcoRI-to-BglII fragment was gel purified and ligated to a gel-purified BglII-to-HindIII fragment of pABN2 and a gel-purified HindIII-to-EcoRI fragment of pNApl5. This reconstructs the plasmid in a "pABN2" backbone. The deletion site was sequenced across by the method of Maxam and Gilbert (17) , confirming that the coding region remains in frame.
(vii) pABGP. pABGP was generated from pABN2. pABN2 was digested partially with PstI, and single-cut linear DNA was gel purified. This DNA was treated with the Klenow fragment to remove the single-stranded ends, and EcoRI linkers were ligated on and then digested with EcoRI to remove excess linkers and cut the plasmid at the end of v-abl in pABN2 (corresponding to what was the ClaI site of M-MuLV). The DNA was then ligated to close the circle and used to transform E. coli. Ampicillin-resistant colonies were screened for the EcoRI linker site at the desired PstI site.
RESULTS
p15 and p12 deletions in gag. We have previously shown that deletion of all but the first 34 amino acids of gag in plasmid pXgl results in a virus which transforms fibroblastic cells but has lost the ability to transform lymphoid cells (21) . To localize the sequences in gag required for this effect, we made smaller deletions within gag. Because of a strong tendency of A-MuLV strains with a full C-terminal region to delete during passage of transformed cells (21, 45) , plasmid pABX2, lacking 60 kd of C-terminal v-abl coding sequence, was the initial starting plasmid for these studies. Two deletions were made: pXApl5, deleting amino acids 38 to 138 of gag (mainly p15 and 21 bases in p12), and pXApl2, deleting amino acids 163 to 228 of gag (in p12 and a bit in p30; Fig. 1 and above). These plasmids were transfected into NIH/3T3 cells, along with helper virus M-MuLV DNA, to enhance the transfection efficiency (8) . As expected, all three plasmids transformed NIH/3T3 cells at similar efficiencies of ca. 500 foci per ,ug of DNA.
To produce stocks of virus from the deleted plasmids, individual foci of transfected, transformed cells were picked and ascertained to contain the input viral genomes. For the parental plasmid, pABX2, we were able to isolate a cell line, X2B, containing only the expected genome as shown by abl-specific hybridization of cellular DNA cleaved by restriction enzymes in the long terminal repeats and fractionated by electrophoresis (9, 32) Fig. 2 ). Although XAp15-1 contains an Abelson protein precipitable with anti-p12 but not anti-p15 antiserum (Fig. 2, lanes 1 and 2) , the Abelson protein in 450-93 was precipitable with both antisera (lanes 3 and 4) Due to the spontaneous deletion problems encountered with pABX2, we extended these studies by using a slightly more truncated plasmid, pABN2, which lacks 377 3' bases of v-abl present in pABX2 (Fig. 1) We made two deletions in pABN2 (Fig. 1) 90, 85, and 75 kd, were found in N2, Ndl-1, and NAp15-1, respectively (Fig. 3) . Virus from NAp1S-1, although it had a high titer on NIH/3T3 cells, had entirely lost its lymphoidtransforming activity and showed no reversion ( Table 1) . The efficiency of lymphoid transformation was also greatly reduced for virus from Ndl-1. Three of the rare transformants of Ndl-1 virus were analyzed to determine whether the low level of transformation was due to recombination. All had the same size of Abelson protein as in Ndl-1, indicating that they had not reverted (data not shown).
Expression of the p15-deleted virus in Iymphoid cells. To examine why p15 sequences might be required for lymphoid transformation, we investigated the various properties of the deleted proteins expressed in transformed NIH/3T3 cells but did not find any significant differences from wild-type Abelson proteins. The gag-deleted proteins are still phosphorylated on tyrosine and elevate the in vivo phosphotyrosine level (21) . Fractionation of cells into particulate and soluble fractions by 100,000 x g centrifugation failed to show a difference: approximately equivalent amounts of the Abelson protein were present in each fraction (data not shown).
Not finding any differences in the protein expressed in fibroblastic cells, we sought differences directly in lymphoid cells. Because the p15-deleted genomes do not transform lymphoid cells and because lymphoid cells do not grow extensively unless they are transformed, we could not directly produce a cell that contained only the deleted genome. We could, however, introduce the genomes nonselectively into a previously transformned cell line and screen for their uptake. To this end we used the chemically induced lymphoma cell line 70Z/3 (20) . It is slightly more advanced in its differentiated state than most A-MuLV-transformed lymphoid cell lines but has the advantage of lacking any known transforming virus. These cells were infected with virus stocks from either N2 or NAp1S-1 at a high multiplicity of infection and immediately cloned as single cells in microtiter dishes. The clonal cell lines were then screened for uptake of A-MuLV by testing immunoprecipitates of cells for autophosphorylation of an Abelson protein (42) . Approximately 50% of the single-cell clones were positive in this assay. It was immediately evident that in five separate clones containing the p15-deleted genome, the autophosphorylation activity in the deleted P75 protein was 1/20th of that seen with the fully transforming P90 protein (Fig. 4,  lanes 1 through 5) . No autophosphorylation was evident in immunoprecipitates from a negative control, 70Z/M (lane 7), which was a single-cell clone of 70Z/3 infected only with M-MuLV. There was a negligible difference in autophosphorylation activity between the transformed fibroblast cells, N2 and NAp15-1, containing the wild-type and p15-deleted genomes (lanes 8 and 9).
To determine whether the p15-deleted genome was being expressed efficiently in 70Z/3 cells, we made total cellular RNA from 70Z/90A (containing the undeleted virus), 70Z/d2 (containing the p15-deleted virus), and 70Z/M (with no A-MuLV genome) cells. The RNA was electrophoretically size fractionated and hybridized to a v-abl-specific probe. There were roughly equivalent amounts of A-MuLV RNA in 70Z/90A and 70Z/d2 (Fig. 5) , indicating that there is no block to expression of the p15-deleted genome in lymphoid cells. c-abl RNA was also evident in all three lines.
To examine the synthesis and steady-state levels of Abelson proteins in these cells, we performed two experiments.
In one we pulse-labeled the cells with [35S]methionine and immunoprecipitated the A-MuLV proteins. Both P90 and the p15-deleted P75 could be detected (Fig. 6) . Although P75 was synthesized at a somewhat lower rate, the difference is not extensive enough to account for the differences in autophosphorylation activity.
We next used the immunoblotting technique to probe for the steady-state level of A-MuLV proteins. Lysates were prepared from each of the cell lines and electrophoresed through an SDS-7% polyacrylamide gel. The proteins were transferred to nitrocellulose and probed with a rabbit antibody (provided by Jean Wang) directed against v-abl protein purified from bacteria expressing the 5' 1.2 kilobases of v-abl. Bound antibody was detected by using a second antibody stain of goat anti-rabbit immunoglobulin G conjugated to peroxidase. P75 and P90 were easily detectable in the fibroblastic cell lines NAp1S-1 and N2 (Fig. 7, lanes 2 and  3 ), although at a redued level in NAp1S-1. P90 was also clear in 70Z/90A (lane 8), but P75 was not detectable in 70Z/d2 (lane 7). We judge that the lower limit of sensitivity is less than 10% of the P90 level because we could detect P90 when its lysate was diluted with that of 7OZ/M in a ratio of 1:10 (lane 9). Thus, although P75 is synthesized at appreciable rates, it does not accumulate to the steady-state levels of P90, presumably due to the specific instability of this protein in lymphoid cells.
Attempts to use pulse-chase experiments to demonstrate this instability directly have been confounded by background bands that comigrate with P75 and increase in intensity with chase time. Nonetheless, our estimate from several experiments is that the half-life of P90 in 70Z/90A is ca. 7 h, whereas the half-life of P75 in 70Z/d2 is ca. 1 h (data not shown).
To examine whether the instability was specific to 70Z/3 cells and to directly examine A-MuLV-transformed cells, we introduced the p15-deleted virus into a lymphoid cell line already transformed by a competent A-MuLV[P120] strain. This cell line, 2M3, is a nonproducer; because it does not contain M-MuLV, it has no superinfection barrier (44) . A positive cell line, M8, was derived by superinfection with virus from NAp15-1 and then tested by pulse-labeling and immunoblotting for synthesis and levels of the p15-deleted protein. P75 was synthesized in amounts similar to those of the endogenous P120, the Abelson transforming protein of 2M3 cells (Fig. 8) . Immunoblotting showed undetectable P75, whereas P120 was clearly present (Fig. 7, lane 5 compartment. p15 is in fact the most hydrophobic of the gag proteins and will partition partially in membranes (2, 35) . This is likely to be due in part to the fatty acid myristate, which is covalently linked to the N terminus of p15 (10, 30) . The Abelson protein is also myristylated on its N terminus due to its p15 sequences (29) . We found that the first 34 amino acids of gag present in the gag-deleted Abelson protein is sufficient for the protein to become myristylated (unpublished data). To test whether the p15-deleted protein, P75, fractionated differently than P90 in 7OZ/3 cells, we fractionated 70Z/90A and 70Z/d2 cells and followed the A-MuLV proteins by autophosphorylation (Fig. 9) . The cells were fractionated by 100,000 x g centrifugation into particulate (P100) and soluble (S100) fractions. These two fractions were then immunoprecipitated and analyzed for autophosphorylation activity. Although, again, the total autophosphorylation activity of P75 was less than 1/20th that of P90 (lanes 1 and 4) , the activity that remained appeared to fractionate in a similar manner to that of P90, with a ratio of roughly 2:1 of P100 versus S100 activity (lanes 2, 3, 5, and 6) .
Effect of v-abl deletions on lymphoid transformation. As described above, A-MuLV genomes deleted in v-abl back to the XhoI or NarI sites in plasmids pABX2 and pABN2 q\@<\,OQ<X,+\b\,O&, P120- 1 through 3, or 1 x 106, lanes 4 through 9) were extracted, fractionated on an SDS-7% polyacrylamide gel, and transferred to nitrocellulose as described in the text. After a blocking step, the nitrocellulose filter was incubated with a 1:1,000 dilution of R-antiabl, washed, and incubated with peroxidase conjugated goat antirabbit immunoglobulin G. After washing, the specific signal was developed with 3-3'-diaminobenzidene. These steps are all described in the text. The cell lines used are indicated above each lane and described in the legend to (Table 1) . These two plasmids, however, have more of v-abl than is required for fibroblast transformation. We have previously found (21) that a gag-deleted plasmid, pAB-P, containing only the 5' 1.2 kilobases of v-abl, will transform NIH/3T3 cells. As this plasmid was deleted in gag, we could not test whether this minimum transforming region was also sufficient for lymphoid transformation. For this reason we constructed a plasmid containing gag fused to the 5' 1.2 kilobases of v-abl. This plasmid, pABGP, is exactly the same as pABN2, except that it extends to a PstI site in v-abl rather than a Narl site (see above for details of construction). The three plasmids pABGP, pABN2, and pABX2 were identical, except that they contain 1,221, 1,484, and 1,861 bases of v-abl, respectively. Plasmid pABGP transformed NIH/3T3 cells as expected, and we established a line, GP-2, from one of the foci. This line contains only the expected genome and the predicted 80-kd Abelson protein (data not shown).
We harvested virus from this line and tested it for lymphoid transformation. It 
DISCUSSION
We have examined why a previously described large deletion of gag-coding sequence from A-MuLV specifically abolished lymphoid cell transforming activity (21) . We found that a deletion of only p15 sequences has the same dramatic effect, implying a localization of the crucial sequence to this subregion of gag. We further found that the p15 deletion labilized the protein in two different lymphoid cells, implying that the p15 sequences function to stabilize the protein specifically in lymphoid cells.
Localization to p15. The large gag deletion studied previously brought the N-terminal 34 amino acids of gag next to v-abl, and it could have been this specific juxtaposition of sequences that affected lymphoid-transforming activity rather than the loss of sequence due to deletion. This now seems unlikely because the p15 deletion described here left amino acids 1 to 37 (counting the initial methionine as number 1) and 139 to 236 of gag intact. Thus, the deletion left in place the 97 amino acids next to v-abl but had the same effect. The specificity of the effect to p15 sequences is indicated by the maintenance of lymphoid-transforming activity in a p12 deletion mutant. Furthermore, the small number of lymphoid transformants arising from infection of bone marrow cells with the p15-deleted virus could be accounted for by reacquisition of the p15 sequences, presumably via recombination with the helper virus. This again emphasizes the requirement of these p15 sequences for lymphoid transformation. Finally, a smaller deletion at the C terminus of p15 (amino acids 114 to 138 in pNdl) also caused a large reduction in lymphoid transformation, although there was some residual activity (Table 1) .
In searching for an explanation of the role of p15 sequences, we noted that p15 is the most hydrophobic of the gag proteins and will partition into membranes (2, 35) . In part, this is probably due to the myristyl group covalently linked to the N terminus of p15 (10) . The A-MuLV protein is also myristylated on the end of its sequences (29), but we have found that the N-terminal 34 amino acids of gag still present in the gag-deleted protein are sufficient for signaling the myristylation (unpublished data), implying that signaling myristylation is probably not the function of the required p15 sequence. In addition, fractionation of the proteins in lymphoid cells into particulate and soluble fractions by 100,000 x g centrifugation revealed no difference in localization of the gag-deleted protein. As found for P16 ag-abI (40) (21) and now the smaller deletions within p15 have shown that some of the gag sequences in A-MuLV are integral parts of this transforming virus. These sequences are required to stabilize the transforming protein in lymphoid cells. If the recombination event to form the virus had occurred at amino acid 34 of p15, rather than within p30, our data clearly indicate that the virus would not be transforming and would never have been detected. (Remember that in animals A-MuLV transforms lymphoid cells but not fibroblasts.) Whether the inclusion of gag sequences (or some other foreign sequence) is a necessary event in the modification of the nononcogenic proto-oncogene, c-abl, to form the v-abl oncogene is a more difficult question to answer. Because the N terminus of c-abl is missing from A-MuLV (37, 38), we do not know whether the gag sequence is replacing the normal function of the c-abl N-terminal sequence or whether gag is imparting new properties to the abl protein. B. Mathey-Prevot and D. Baltimore (unpublished data) have shown that the N terminus of pp60src will replace the gag function in A-MuLV lymphoid transformation, showing that gag is not unique in providing the stabilizing activity.
Although the deletion of the c-abl N terminus and its replacement by gag sequence may be the events that activate c-abl to become the v-abl oncogene, there are other differences between c-abl and v-abl. For one thing, there are many point mutations in v-abl relative to c-abl which may be important (38) . Also, due to the strong retrovirus promoter, there is an elevated expression of the Abelson transforming protein over the c-abl product of ca. 14-fold (37) . Any or all of these alterations could be responsible for making c-abl into an oncogene.
The reason p15 sequences stabilize the A-MuLV protein specifically in lymphoid cells is not clear. Because p15 is hydrophobic, we suspected that it might affect the localization of the protein to the membrane. Crude fractionation by 100,000 x g centrifugation, however, suggests that, at least for the autophosphorylation activity that remains, there is no difference in localization. Perhaps there are more subtle differences in localization, such as localization to specific organelles or complexes which might stabilize the protein. A simpler hypothesis is that deletion in p15 may simply destabilize the protein due to changes in secondary structure which make it more accessible to proteases. For this to be true, either these proteases must be specific to lymphoid cells or the change in secondary structure must not be as pronounced in fibroblasts.
A final point made by these experiments is that the minimum transforming region of v-abl is the same for fibroblasts and lymphoid cells. The derivation of lymphoid clones transformed by the GP-2 virus demonstrates this point; it has a v-abl region with as small a deletion of v-abl sequence as any that will transform fibroblasts (20a, 21) . The GP-2 virus is inefficient at transformation but also, for unknown reasons, has a low titer. Previous data showed that C-terminal v-abl sequences play a quantitative but not qualitative role in A-MuLV transformation (21, 27) ; perhaps GP-2 shows this effect most dramatically, but until highertiter stocks are available this point will remain unclear.
